<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>13</volume><submitter>Ivanovska A</submitter><pubmed_abstract>&lt;h4>Objective&lt;/h4>Osteoarthritis (OA) is a widespread and debilitating joint disease characterized by synovial inflammation, cartilage degeneration, and chronic joint pain. Mesenchymal stromal cells (MSCs) have shown therapeutic efficacy for many diseases with a strong inflammatory profile, including OA. However, the disease-specific mechanisms of action underpinning the effects of post-local MSC delivery remain unaddressed. In this study, we aimed to characterize the disease-induced profile of MSCs following exposure to the &lt;i>in vivo&lt;/i> osteoarthritis environment.&lt;h4>Methods&lt;/h4>Murine syngeneic GFP + bone marrow-derived MSCs (BM-MSCs) were delivered &lt;i>via&lt;/i> intra-articular injection in a mouse collagenase-induced osteoarthritis (CIOA) model (n = 8). BM-MSCs were retrieved by cell so</pubmed_abstract><journal>Frontiers in cell and developmental biology</journal><pagination>1521437</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11980424</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Identification of disease-stage therapeutic responses of mesenchymal stromal cells retrieved from murine osteoarthritic joints.</pubmed_title><pmcid>PMC11980424</pmcid><pubmed_authors>Burke A</pubmed_authors><pubmed_authors>Morris DW</pubmed_authors><pubmed_authors>English K</pubmed_authors><pubmed_authors>McLoughlin S</pubmed_authors><pubmed_authors>Mukeria E</pubmed_authors><pubmed_authors>Reilly J</pubmed_authors><pubmed_authors>Ritter T</pubmed_authors><pubmed_authors>Raman S</pubmed_authors><pubmed_authors>O'Brien A</pubmed_authors><pubmed_authors>Johnstone B</pubmed_authors><pubmed_authors>Hennessy C</pubmed_authors><pubmed_authors>Dooley C</pubmed_authors><pubmed_authors>Ryan AE</pubmed_authors><pubmed_authors>Kamath R</pubmed_authors><pubmed_authors>Mancuso P</pubmed_authors><pubmed_authors>Murphy JM</pubmed_authors><pubmed_authors>Shaw G</pubmed_authors><pubmed_authors>Riet DV</pubmed_authors><pubmed_authors>Barry F</pubmed_authors><pubmed_authors>Ivanovska A</pubmed_authors><pubmed_authors>Levesque MC</pubmed_authors><pubmed_authors>Hawthorne I</pubmed_authors></additional><is_claimable>false</is_claimable><name>Identification of disease-stage therapeutic responses of mesenchymal stromal cells retrieved from murine osteoarthritic joints.</name><description>&lt;h4>Objective&lt;/h4>Osteoarthritis (OA) is a widespread and debilitating joint disease characterized by synovial inflammation, cartilage degeneration, and chronic joint pain. Mesenchymal stromal cells (MSCs) have shown therapeutic efficacy for many diseases with a strong inflammatory profile, including OA. However, the disease-specific mechanisms of action underpinning the effects of post-local MSC delivery remain unaddressed. In this study, we aimed to characterize the disease-induced profile of MSCs following exposure to the &lt;i>in vivo&lt;/i> osteoarthritis environment.&lt;h4>Methods&lt;/h4>Murine syngeneic GFP + bone marrow-derived MSCs (BM-MSCs) were delivered &lt;i>via&lt;/i> intra-articular injection in a mouse collagenase-induced osteoarthritis (CIOA) model (n = 8). BM-MSCs were retrieved by cell so</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025</publication><modification>2025-07-07T03:09:01.894Z</modification><creation>2025-07-07T03:09:01.894Z</creation></dates><accession>S-EPMC11980424</accession><cross_references><pubmed>40206403</pubmed><doi>10.3389/fcell.2025.1521437</doi></cross_references></HashMap>